Vistagen announces pricing of $100 million underwritten offering

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen therapeutics, inc. (“vistagen”) (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“cns”) disorders, today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock (or pre-funded warrants in.
VTGN Ratings Summary
VTGN Quant Ranking